Vor bio appoints seasoned healthcare institutional investor, han choi, m.d., ll.m., as chief financial officer

Cambridge, mass., sept. 30, 2024 (globe newswire) -- vor bio (nasdaq: vor), a clinical-stage cell and genome engineering company, today announced the appointment of han choi, m.d., ll.m., as its new chief financial officer, effective immediately. dr. choi will join the vor bio leadership team and will report directly to the company's president and chief executive officer, dr. robert ang.
VOR Ratings Summary
VOR Quant Ranking